Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07672431 | Study of the TheraBionic P1 Device in Patients With Metastatic Triple Negative Breast Cancer After Progression | not yet recruiting | N/A | 24 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07672743 | A Phase II Study of Radiation Therapy to Treat Refractory Breast Cancer | not yet recruiting | N/A | 29 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 29, 2026 |
| clinicaltrials |
| NCT07671690 | Prediction of Neoadjuvant Therapy Efficacy and Prognosis for Breast Cancer Based on Multimodal Data | not yet recruiting | N/A | 1,800 | Yunnan Cancer HospitalOTHER | 0 | Jun 26, 2026 | clinicaltrials |
| NCT07668362 | Prospective Cohort Study of Local Recurrence After Radical Breast Cancer Resection | not yet recruiting | — | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07669610 | An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC(TRIBE) | not yet recruiting | Phase 3 | 140 | Fudan UniversityOTHER | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07217990 | Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer(NoCUT-BC) | not yet recruiting | Phase 1 / Phase 2 | 84 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07665346 | A Pre-post Pilot of a Smartphone Intervention | not yet recruiting | N/A | 44 | University of VirginiaOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07581314 | Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) | not yet recruiting | Phase 1 / Phase 2 | 76 | Telomir Pharmaceuticals, Inc.INDUSTRY | 0 | Jun 23, 2026 | clinicaltrials |
| NCT07662252 | Circulating Tumor DNA Dynamics to Optimize Neoadjuvant Therapy in HER2-Positive and Triple-Negative Breast Cancer(NEOSHED) | not yet recruiting | — | 186 | Federico II UniversityOTHER | 0 | Jun 23, 2026 | clinicaltrials |
| NCT07663006 | Breast and Cervical Cancer Stigma in Rwanda | not yet recruiting | N/A | 1,116 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07654257 | Single FrAction Interstitial BreaSt BracHytherApy(SASHA) | not yet recruiting | Phase 2 | 134 | Virginia Commonwealth UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07657169 | Molecular Subtype-Guided Postoperative Radiotherapy for Phyllodes Tumor of the Breast: A Randomized Controlled Trial | not yet recruiting | N/A | 160 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07657442 | Risk-Stratified Hypofractionated Radiotherapy After Breast-Conserving Surgery for Early Breast Cancer | not yet recruiting | N/A | 649 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07658183 | A Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer | not yet recruiting | Phase 2 | 120 | Shanghai Best-Link Bioscience, LLCINDUSTRY | 0 | Jun 18, 2026 | clinicaltrials |
| NCT07644910 | Nudging Preventive Screening Via Message Framing and Bundling | not yet recruiting | N/A | 235,000 | University of ChileOTHER | 0 | Jun 17, 2026 | clinicaltrials |
| NCT07653698 | Cachexia and Gut Microbiota in Patients With Breast Cancer Receiving Home Care(GM_ANT) | not yet recruiting | N/A | 140 | Fondazione ANT Franco Pannuti ETSOTHER | 0 | Jun 17, 2026 | clinicaltrials |
| NCT07649902 | Artificial Intelligence Powered Digital Education Based on the Neuman Systems Model for Breast Cancer Patients Receiving Radiotherap | not yet recruiting | N/A | 38 | Ataturk UniversityOTHER | 0 | Jun 16, 2026 | clinicaltrials |
| NCT07644455 | Percutaneous Biopsy After Neoadjuvant Chemotherapy.(VAC-Biopsy) | not yet recruiting | N/A | 100 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07102940 | Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer | not yet recruiting | Phase 2 | 50 | George Washington UniversityOTHER | 0 | Jun 11, 2026 | clinicaltrials |
| NCT07560475 | Exploratory Study of SHR-A1811 Via Different Administration Routes in Patients | not yet recruiting | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07618923 | Neoadjuvant Dalpiciclib + AI → SHR-A1811 for HR+/HER2-Low Breast Cancer(TD-DASHER-01) | not yet recruiting | Phase 2 | 20 | Tang-Du HospitalOTHER | 0 | Jun 11, 2026 | clinicaltrials |
| NCT07643428 | Cancer Lipidome Adaptation and Resculping Through Omega-3 PUFAs in Breast Tumors(CLARA) | not yet recruiting | Phase 2 | 35 | Medical College of WisconsinOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07643584 | De-Escalation of Axillary Management in Advanced Nodal Disease(DEMAND) | not yet recruiting | Phase 2 | 120 | University of Kansas Medical CenterOTHER | 0 | Jun 11, 2026 | clinicaltrials |
| NCT07639970 | Evaluation of [⁶⁸Ga/¹⁷⁷Lu]HT547: Safety, Biodistribution, and Dosimetry in Solid Tumors | not yet recruiting | Early Phase 1 | 20 | Hua PangOTHER | 0 | Jun 10, 2026 | clinicaltrials |
| NCT07598084 | Non-Contrast Breast MRI Diagnosis and Risk Stratification Using DWI-Generated Synthetic Contrast Enhancement | not yet recruiting | — | 12,000 | Peking University People's HospitalOTHER | 0 | Jun 9, 2026 | clinicaltrials |
| NCT07635654 | Disease Extent in Stage IV Lobular Carcinoma: the Aid of Imaging and Liquid Biopsy Analyses(DELILA) | not yet recruiting | N/A | 43 | KU LeuvenOTHER | 0 | Jun 9, 2026 | clinicaltrials |
| NCT07623642 | A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. | not yet recruiting | Phase 2 | 227 | GV20 TherapeuticsINDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07630103 | Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer | not yet recruiting | Phase 2 | 100 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07630948 | Adherence and Safety of Ribociclib Plus Aromatase Inhibitors in Patients With Early Stage, HR+ and HER2- Breast Cancer(riboADHERE) | not yet recruiting | Phase 4 | 90 | Institute of Oncology LjubljanaOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07627269 | Late Scan Time-point Optimalisation of 18F-Fluoroestradiol for the Large Field-of-view (LAFOV) PET/CT Scanner. | not yet recruiting | N/A | 8 | University Medical Center GroningenOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07357948 | Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapy(OMICHIR) | not yet recruiting | N/A | 150 | Institut CurieOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07623226 | Super-Resolution Ultrasound Imaging for Assessing Response to Neoadjuvant Chemotherapy in Breast Cancer | not yet recruiting | — | 150 | Anhui Provincial Cancer HospitalOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT06812208 | Strategies to Decentralize Breast Ultrasound in Rwanda | not yet recruiting | N/A | 1,792 | Brigham and Women's HospitalOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07616856 | Post-market Evaluation of LumiSystem: Intraoperative Margin Performance and Clinical Utility (IMPACT) Registry(IMPACT) | not yet recruiting | — | 1,500 | Lumicell, Inc.INDUSTRY | 0 | Jun 1, 2026 | clinicaltrials |
| NCT07618390 | A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer. | not yet recruiting | Phase 2 | 160 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Jun 1, 2026 | clinicaltrials |
| NCT07619066 | A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.(AGATHA) | not yet recruiting | Phase 2 | 25 | MedSIROTHER | 0 | Jun 1, 2026 | clinicaltrials |
| NCT07405385 | REstoring Metabolic FLEXibility Through Combined Exercise in Breast Cancer Survivors: A Randomized Controlled Trial.(REFLEX) | not yet recruiting | N/A | 44 | University of Castilla-La ManchaOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07610499 | Creating Opportunities For Personal Empowerment (COPE) In Women With Breast Cancer During First-Line Therapy: A Pilot Randomized Controlled Trial | not yet recruiting | N/A | 40 | M.D. Anderson Cancer CenterOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07610525 | Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial | not yet recruiting | Phase 2 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07610733 | Impact of Formulation Change on Ovarian Suppression in Young Breast Cancer Patients.(IFOCOS) | not yet recruiting | Phase 2 | 100 | Fudan UniversityOTHER | 0 | May 28, 2026 | clinicaltrials |
| NCT07578116 | Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis | not yet recruiting | Phase 3 | 562 | SWOG Cancer Research NetworkNETWORK | 0 | May 27, 2026 | clinicaltrials |
| NCT07599618 | Evaluation of a Patient-Centered Decision-Making Support Tool for Older Adults With Advanced Breast Cancer and Their Care Partners(PCDM) | not yet recruiting | N/A | 150 | University of RochesterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07575750 | Efficacy of Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Aromatase Inhibitor-induced Arthralgia (AIA)(AROVAGUE) | not yet recruiting | N/A | 60 | Institut Cancerologie de l'OuestOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07601152 | Clinical and Biological Study of Early-onset Breast Cancer and the Influence of the Reproductive Cycle on the Aggressiveness of the Disease(ARTEMIS) | not yet recruiting | — | 1,000 | Institut Cancerologie de l'OuestOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07601620 | A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer | not yet recruiting | Phase 1 | 258 | Shanghai Henlius BiotechINDUSTRY | 0 | May 22, 2026 | clinicaltrials |
| NCT07604441 | Chemotherapy-Induced Peripheral Neuropathy - Additional Evaluation in Breast Cancer Survivors(NEURO-BREAC-02) | not yet recruiting | N/A | 28 | University Hospital Schleswig-HolsteinOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07605195 | Research on the Whole-Process Intelligent Diagnosis and Treatment of Digital Breast Tomosynthesis Based on Deep Learning | not yet recruiting | N/A | 5,000 | Yunnan Cancer HospitalOTHER | 0 | May 22, 2026 | clinicaltrials |
| NCT07562399 | Adjuvant Endocrine Therapy Adherence Intervention Pilot in Rwanda | not yet recruiting | N/A | 224 | Dana-Farber Cancer InstituteOTHER | 2 | May 20, 2026 | clinicaltrials |
| NCT07599098 | Effects of a Pilates Studio Program on Quality of Life and Functional Capacity of Women Undergoing Breast Cancer Treatment(Cancer) | not yet recruiting | N/A | 50 | Federal University of MaranhaoOTHER | 0 | May 20, 2026 | clinicaltrials |
| NCT07599137 | Abemaciclib Dose Escalation in Early High-Risk Breast Cancer Adjuvant Therapy(ADES) | not yet recruiting | Phase 4 | 86 | Peking University Cancer Hospital & InstituteOTHER | 0 | May 20, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 29, 2026source: clinicaltrials